RedHill Biopharma Ltd (RDHL)

[Amatuer17]

RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017

Select recent milestones include:

Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. by RedHill's GI-focused sales force with two GI specialty products, Donnatal® and EnteraGam®
Positive top-line results from the Phase III GUARD study with BEKINDA® (RHB-102) 24 mg for acute gastroenteritis and gastritis